OBJECTIVES
1. Name the two radiopharmaceuticals approved by the FDA for performance of RIT Procedures
2. Describe how patient- specific doses are determined and identify the typical dose for each radiopharmaceutical
3. List several eligibility criteria for undergoing the RIT procedure
4. Name the pretreatment designed specifically for Bexxar
5. Describe the special radiation safety considerations when administering Bexxar to patients
6. Briefly describe the results of clinical trials in the US for the past 10 years
7. List potential long-term effects that could result from this treatment

RADIOPHARMACEUTICALS

I ¹³¹ BEXXAR® (Spectrum Pharmaceuticals, Inc)

● Current Management of NHL
● Rational for the Use of RIT in Follicular NHL
● Characteristics, Clinical Pharmacology and Rationale for Dosing Regimen
● Patient Specific Dosing using Dosimetry
● Biodistribution Images
● Clinical Studies
● Safety
● Radiation Safety Issues
● Dose Preparation

Y ⁹⁰ ZEVALIN® (GlaxoSmithKline)

Introduction to NHL & RIT

Non Hodgkins Lymphoma
Patient Indications

● Timeline for the Zevalin Treatment
● Infusion Techniques for Zevalin
● Imaging of ¹¹¹In Zevalin
● Radiation Safety
● Patient Safety and Efficacy